Literature DB >> 12646685

Bisphosphonates and ocular inflammation.

Frederick W Fraunfelder, Frederick T Fraunfelder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12646685     DOI： 10.1056/NEJM200303203481225

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Ocular side effects of bisphosphonates: A case report and literature review.

Authors:  Meredith McKague; Derek Jorgenson; Kelly A Buxton
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

2.  Acute retinal pigment epitheliitis associated with intravenous bisphosphonate.

Authors:  J S Gilhotra; A K Gilhotra; I M Holdaway; M L Donaldson
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

Review 3.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Zoledronic acid induced unilateral anterior uveitis.

Authors:  Shipra Gupta; Abhishek Onkar; Tushar Vashisht
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

5.  Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.

Authors:  Beate Aurich Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2005-08-31       Impact factor: 4.507

Review 6.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

7.  Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.

Authors:  D V Patel; M Bolland; Z Nisa; F Al-Abuwsi; M Singh; A Horne; I R Reid; C N J McGhee
Journal:  Osteoporos Int       Date:  2014-09-04       Impact factor: 4.507

Review 8.  Zoledronic acid in genitourinary cancer.

Authors:  M A Climent; U Anido; M J Méndez-Vidal; J Puente
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

Review 9.  Safety of drugs used in the treatment of osteoporosis.

Authors:  Cora McGreevy; David Williams
Journal:  Ther Adv Drug Saf       Date:  2011-08

10.  A case report: zoledronic acid-induced anterior uveitis.

Authors:  Saadettin Kilickap; Yasemin Ozdamar; M Kadri Altundag; Omer Dizdar
Journal:  Med Oncol       Date:  2007-09-08       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.